NCT03204734
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 70 Years (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with central nervous system (CNS) metastasis
https://ClinicalTrials.gov/show/NCT03204734